429 related articles for article (PubMed ID: 1945409)
1. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
2. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
3. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
5. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
Polack A; Feederle R; Klobeck G; Hörtnagel K
EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
[TBL] [Abstract][Full Text] [Related]
6. c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo.
Mautner J; Behrends U; Hörtnagel K; Brielmeier M; Hammerschmidt W; Strobl L; Bornkamm GW; Polack A
Oncogene; 1996 Mar; 12(6):1299-307. PubMed ID: 8649832
[TBL] [Abstract][Full Text] [Related]
7. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW
Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463
[TBL] [Abstract][Full Text] [Related]
8. Two antisense promoters in the immunoglobulin mu-switch region drive expression of c-myc in the Burkitt's lymphoma cell line BL67.
Apel TW; Mautner J; Polack A; Bornkamm GW; Eick D
Oncogene; 1992 Jul; 7(7):1267-71. PubMed ID: 1620543
[TBL] [Abstract][Full Text] [Related]
9. Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus.
Wilda M; Busch K; Klose I; Keller T; Woessmann W; Kreuder J; Harbott J; Borkhardt A
Genes Chromosomes Cancer; 2004 Oct; 41(2):178-82. PubMed ID: 15287031
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
11. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.
Kanda K; Hu HM; Zhang L; Grandchamps J; Boxer LM
J Biol Chem; 2000 Oct; 275(41):32338-46. PubMed ID: 10931834
[TBL] [Abstract][Full Text] [Related]
12. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
13. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
14. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
15. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
Madisen L; Groudine M
Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
[TBL] [Abstract][Full Text] [Related]
16. Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer.
Hu HM; Kanda K; Zhang L; Boxer LM
Leukemia; 2007 Apr; 21(4):747-53. PubMed ID: 17287852
[TBL] [Abstract][Full Text] [Related]
17. Topological organization of the MYC/IGK locus in Burkitt's lymphoma cells assessed by nuclear halo preparations.
Rätsch A; Joos S; Kioschis P; Lichter P
Exp Cell Res; 2002 Feb; 273(1):12-20. PubMed ID: 11795942
[TBL] [Abstract][Full Text] [Related]
18. Allele-specific activation of the c-myc gene in an atypical Burkitt's lymphoma carrying the t(2;8) chromosomal translocation 250 kb downstream from c-myc.
Tachibana K; Takayama N; Matsuo K; Kato S; Yamamoto K; Ohyama K; Umezawa A; Takano T
Gene; 1993 Feb; 124(2):231-7. PubMed ID: 8444346
[TBL] [Abstract][Full Text] [Related]
19. The block of elongation in c-myc exon 1 is abolished in Burkitt's lymphoma cell lines with variant translocation.
Eick D; Polack A; Kofler E; Bornkamm GW
Oncogene; 1988 Oct; 3(4):397-403. PubMed ID: 3078949
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
